(R)-2,5,7,8-Tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-ol

Catalog No. :
ACNYEV624
CAS No. :
59-02-9
Molecular Formula :
C29H50O2
Molecular Weight :
430.72

IUPAC Name:(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-ol

(R)-2,5,7,8-Tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-ol structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100g98%$53.00Login to see priceIn stockInquiry
500g98%$227.00Login to see priceIn stockInquiry
1000g98%$389.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(R)-2,5,7,8-Tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-ol
IUPAC Name(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-ol
MDL No.MFCD00072045
Molecular FormulaC29H50O2
Molecular Weight430.72
SMILESOC1=C(C)C(C)=C2C(CC[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)O2)=C1C
InChI KeyGVJHHUAWPYXKBD-IEOSBIPESA-N
SynonymVita plus E | (+/-)-alpha-Tocopherol | a-Vitamin E | Covitol F 1000 | 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-, (2R)- | Etavit | Tenox GT 1 | 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8
CAS No.59-02-9
PubChem CID14985

Synthetic Route by SureRoute

1. ACNYEV624 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACARDY409 route compound structure diagram
    ACARDY409505-32-8 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Plus
  5. reactant_3 route compound structure diagram
    --
  6. Then
  7. ACNYEV624 route product structure diagram
    ACNYEV62459-02-9 In Stock
Inquiry

2. ACNYEV624 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACNYEV624 route product structure diagram
    ACNYEV62459-02-9 In Stock
Inquiry

Comments (0)